Project title: Commercialisation of a diagnostic imaging system for cancer surgery
Breast cancer is the most common cancer with 2.3M women diagnosed each year globally. The foundation of curative treatment is complete surgical removal of the tumour, usually via breast conserving surgery/lumpectomy (BCS). However, up to 35 per cent of BCS patients will need repeat surgery due to incomplete excision, with huge economic costs (>US$691m/year in US) as well as physical and psychological burdens for patients and families.
OncoRes Medical is developing a novel diagnostic imaging system to guide complete surgical clearance of cancer in breast conserving surgery (BCS).
OncoRes Medical has demonstrated early clinical feasibility of a handheld imaging device to guide real time decision making for surgeons in the surgical cavity, and was granted Breakthrough Device Designation by the US FDA (Food and Drug Administration) (October 2020).
This CTCM funded project will advance the commercialisation of OncoRes' breakthrough device toward a marketed product in Australia and will deliver a critical and important clinical evidence point by conducting a multi-site Australian study.
CTCM Project Round: One
- CTCM Grant: $1,500,000
- Industry Contribution: $1,064,328
Website: OncoRes Medical | LinkedIn: OncoRes Medical